Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Agios Strengthens Team with Key Appointments and Promotion

Published: Monday, May 14, 2012
Last Updated: Monday, May 14, 2012
Bookmark and Share
The appointments include Robert J. DeVita, Ph.D., to the role of vice president of chemistry and Marion Dorsch, Ph.D., to the role of vice president of biology.

In addition to the above appointments, John Evans was promoted to vice president of business development and operations.

“The strength of our science and success of our efforts to date are a direct result of the amazing people at Agios,” said Duncan Higgons, chief operating officer of Agios. “John has made significant contributions to our team and company growth over the last several years. Bob and Marion further expand our R&D leadership, bringing a wealth of experience identifying and successfully developing novel and important drugs. People and culture continue to be cornerstones of Agios’ vision to make medicines that can transform patients' lives.”

Dr. DeVita joins Agios after a highly productive career at Merck Research Laboratories in Rahway, NJ, where he was director of medicinal chemistry. Bob is a co-inventor of more than 42 patents and has led efforts to deliver multiple candidates for human study. He received his Ph.D. at the University of Rochester and was a National Science Foundation postdoctoral fellow at the University of Geneva.

Dr. Dorsch most recently served at Sanofi Oncology, where she headed the cancer biology group and oversaw the drug discovery efforts in Cambridge, Mass. Prior to that, Marion directed research for several oncology programs at the Novartis Institutes for Biomedical Research, and also worked at Millennium Pharmaceuticals. She received her Ph.D. in biology from Free University of Berlin, Germany, and was a postdoctoral student at Columbia University in New York.

Mr. Evans joined Agios in 2009 and is responsible for business development, project and portfolio management, communications, and new product planning. Prior to joining Agios, Mr. Evans served as director of product development at Infinity Pharmaceuticals and worked at McKinsey & Company. He earned an MBA from Wharton and a M.S. in biotechnology from the University of Pennsylvania.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Celgene and Agios Extend Cancer Metabolism Collaboration
Collaboration reflects progress in partnership focused on exploring the transformational science of cancer metabolism.
Thursday, October 13, 2011
Marc Tessier-Lavigne, Ph. D. Joins Agios Board of Directors
Dr. Tessier-Lavigne is president of The Rockefeller University and formerly served as executive vice president for research and chief scientific officer at Genentech.
Monday, October 03, 2011
Agios and Whitehead Institute Collaborate on Nature Publication
Agios Pharmaceuticals announces a publication in the journal Nature that identifies dysregulated activity of the serine pathway as a novel metabolic target in certain breast cancers.
Tuesday, July 19, 2011
Scientific News
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Circadian Clock Controls Insulin and Blood Sugar in Pancreas
Map of thousands of genes suggests new therapeutic targets for diabetes.
Cellular Stress Process Identified in Cardiovascular Disease
Combining the investigative tools of genetics, transcriptomics, epigenetics and metabolomics, a Duke Medicine research team has identified a new molecular pathway involved in heart attacks and death from heart disease.
Predicting Adverse Drug Reactions with Higher Confidence
A new integrated computational method helps predicting adverse drug reaction—which are often lethal—more reliably than with traditional computing methods.
A New Way to Starve Lung Cancer?
Metabolic alterations in lung cancer may open new avenues for treating the disease.
Evidence of How Incurable Cancer Develops
Researchers in the West Midlands have made a breakthrough in explaining how an incurable type of blood cancer develops from an often symptomless prior blood disorder.
Building a Better Liposome
Computational models suggest new design for nanoparticles used in targeted drug delivery.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Antioxidants Cause Malignant Melanoma to Metastasize Faster
Fresh research at Sahlgrenska Academy has found that antioxidants can double the rate of melanoma metastasis in mice.
New Protein Cleanup Factors Found to Control Bacterial Growth
UMass Amherst researchers characterize previously mysterious proteolysis factors.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos